Health Care & Life Sciences » Pharmaceuticals | Myungmoon Pharmaceutical Co. Ltd.

Myungmoon Pharmaceutical Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
201
43
17,864
6,474
8,131
328
Depreciation, Depletion & Amortization
2,255
2,306
2,022
2,003
2,021
1,914
Other Funds
289
310
9
-
4
2,417
Funds from Operations
5,346
4,415
1,425
8,074
9,460
4,658
Changes in Working Capital
3,342
4,451
4,080
2,472
1,436
6,749
Net Operating Cash Flow
2,004
36
5,505
5,601
8,024
11,407
Capital Expenditures
4,726
2,877
3,844
9,464
22,215
Sale of Fixed Assets & Businesses
19
172
289
1,246
135
Purchase/Sale of Investments
415
641
2,872
4,242
2,345
Net Investing Cash Flow
5,493
302
795
4,715
27,650
Cash Dividends Paid - Total
-
270
313
324
1,154
Issuance/Reduction of Debt, Net
3,732
1,566
4,205
7,392
3,521
Net Financing Cash Flow
4,021
1,860
3,876
14,242
2,325
Net Change in Cash
532
1,522
2,423
15,128
17,301
Free Cash Flow
2,718
2,903
9,123
3,746
13,554
Other Sources
22
1,834
-
26
428
Change in Capital Stock
-
254
7
21,958
37
Other Uses
393
73
112
765
3,652

About Myungmoon Pharmaceutical Co.

View Profile
Address
26 Jeyakgongdan 2-gil
Hwaseong GY 18622
Korea, Republic Of
Employees -
Website http://www.mmpharm.co.kr
Updated 07/08/2019
MyungMoon Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include ethical drugs (ETC), over-the-counter drugs (OTC) and indication drugs. The ethical drugs include anesthetic agent, analgesic agent, anti-epileptics, anti-depressants, anti-diabetics, anti-osteoporosis and others.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.